Background: The aim of this study was to search for predictive and prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with everolimus among the components of PI3K/AKT/mTOR pathway.
introduction
Recently, evidence has shown that the mammalian target of the rapamycin (mTOR) pathway in renal cell carcinoma (RCC) has a critical role in oncogenesis, which has made it a potential therapeutic target. mTOR is a cytoplasmic protein kinase that regulates cellular metabolism, growth, proliferation, and angiogenesis through the phosphatidylinositol 3-kinase/AKT/mTOR signalling pathway [1] . PI3K/AKT/mTOR signalling is dysregulated in many cancers, including RCC [2] , and activation of this pathway has been suggested to correlate with aggressive behaviour and poor prognosis in RCC tumours [3] . Inhibition of mTOR has a significant anti-proliferative effect on RCC cell lines [4] .
Promising results in phases I and II studies with everolimus in patients with RCC led to a dedicated a multicentre, international, placebo-controlled phase III trial (RECORD-1) in patients who progressed on cytokines, sunitinib, sorafenib, or both TKIs. However, in the era of molecular targeted therapy, there are no molecular predictor factors of response to mTOR inhibitors which would be helpful for selection of the best treatment strategy for RCC patients. Therefore, we planned this study to seek for predictive and/or prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with everolimus in the PI3K/AKT/mTOR pathway.
patients and methods
patients Inclusion criteria were: Caucasian patients with histologically confirmed clear-cell RCC who had undergone previous treatment with one but no more than two anti-angiogenic therapies; good Karnofsky performance status (≥70), the presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, and adults aged ≥18 years. Adequate haematological parameters (neutrophil count at least 1.5 × 10 9 , platelets, at least 100 × 10 9 /l, haemoglobin at least 9.0 g/dl) and biochemical parameters (bilirubin <2× ULN, AST, ALT < 2.5× ULN or 5× ULN in the presence of hepatic metastases, creatinine clearance >30 ml/min.), a negative pregnancy test in premenopausal women, and signed informed consent to participate in the study was mandatory. 
study design
In this single-centre, open-label, phase II study, patients received everolimus (10 mg/day).
The study treatment continued until disease progression according to RECIST criteria version 1.1. or intolerable toxicity or patient decision to stop.
assessments
The primary efficacy end point was progression-free survival (PFS), defined as the time elapsed between the date of entry into this study and the date of disease progression or the date of last follow-up.
Secondary end points included overall survival (OS), the probability of PFS for at least 6 months, objective response rate, and toxicity determined by adverse events (AEs) and laboratory measures.
Tumour response in measurable lesions was assessed according to RECIST criteria version 1.1. [5] . All included patients who received at least one dose of study medication were assessed for safety. AEs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. [6] .
biomarkers using tumour tissue
Biomarker research using the tumour tissue was carried out only for patients who had written informed consent to participate in biomarker research aside from the study. Exploratory molecular marker assessments were conducted on all available tissue samples (archival paraffin-embedded tissue blocks).
Immunohistochemical (IHC) staining was carried out for phospho-AKT at S473, p70S6K. For IHC evaluation, the following antibodies were used: mouse monoclonal anti-p70S6K, clone 1E12 (AbD Serotec); rabbit monoclonal anti-Phosho AKT 473, clone 736E11 (BioCare).
The analysis was carried out by two independent pathologists who did not have access to clinical data. Evaluation of cytoplasmic staining ( p70S6K) was carried out according to the H-score method, where the final score was calculated by multiplying the percentage of cells stained in each grade by the intensity grade to obtain a summary measure on a 0-300 scale [7] .
Nuclear expression of pAKT473 was also assessed by the semi-quantitative method described above, except that evaluation of the intensity of the reaction was assessed in the cell nucleus. To assess the relationship of nuclear expression of pAKT473 and cytoplasmic p70S6K with clinical features, the analysed group was divided into the median ratio IHC.
For molecular analysis, 4-µm paraffin-embedded sections were microdissected to enrich for tumour, to a minimum of 50% tumour tissue by area. Tumour DNA was extracted using the Prepfiler Express F DNA Kit (Qiagen) using an automatic nucleic acid isolation AutoMate Express machine (Applied Biosystems DNA Extraction PicoPure).
We screened the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov) for common, potentially functional SNPs in four genes involved in the PI3K/ mTOR pathway. The selection of single-nucleotide polymorphisms that could be potential candidates for predictors and/or prognostic factor genes guided by the following criteria: (i) compound described to be associated with cancer, (ii) location within or near the coding and regulatory regions of the gene, and (iii) the minor allele frequency was not <0.2 (20%) in the Caucasian population. Finally, a total of 13 SNPs were selected for genotyping.
statistical analysis
The cut-off date for our analysis was established as 31 January 2013. In order to compare results that did not meet the criteria of a normal distribution, a nonparametric Mann-Whitney U-test was used. Median and life tables were computed using the product-limit estimate by the Kaplan-Meier method and the log-rank test was employed to assess statistical significance; P values <0.05 were considered to indicate statistical significance. Univariate analyses of variables influencing PFS or OS were carried out by log-rank test, which identified a preliminary list of significant factors. All variables that were found to be significant and factors that showed a trend towards significance (P < 0.1) in the univariate analysis were planned for inclusion in a multivariate analysis. Multivariate analyses of PFS and OS were carried out by Cox proportional hazard regression using the forward stepwise method; all variables found to be significant in the univariate analysis were included in the multivariate analysis. We carried out analysis using the statistical package STATISTICA PL (version 7.0; STATSOFT).
results

patient characteristics
The study included 58 patients of (32.8% women and 67.2% men). According to MSKCC criteria, 48.3% of patients were in the group with a favourable prognosis, 39.6% were in the group of intermediate prognostic index and 12.1% of patients were in the poor prognosis group. Table 1 shows details of clinical characterisation patients included in our study. 
toxicity profile
Observed AEs were consistent with those previously reported for everolimus and were mostly grade 1 or 2 severity. The most common haematological AEs were anaemia (76%), lymphopenia (38%), leucopenia (34%), thrombocytopenia (26%), and neutropenia (21%). The most common metabolic AEs were hypercholesterolaemia (67%), hyperglycaemia (64%), and hypertriglyceridaemia (52%). In the study group, non-infectious pneumonia was observed in 12% of patients. Accurate assessment of AEs is presented in supplementary Table S1 , available at Annals of Oncology online.
protein expression within of the PI3K/AKT/mTOR pathway Primary RCC samples (n = 53) were analysed for pAKT473, p70S6K by IHC in the study group. The nuclear expression of pAKT473 was assessed in the primary tumour. The median ICH index was 140 (range 0-250, 95% CI 115-154). The expression of this protein was found in 94.3% (50/53) of patients. High nuclear expression of pAKT473 was found in 49.1% (26/53) of patients, while low expression was seen in 50.9% (27/53) of patients. In 66% of patients, we observed positive expression of the nuclear p70S6K protein in RCC. For dichotomisation of the groups, a positive or negative expression of this protein was adopted. In 34% of patients, we did not find p70S6K expression in RCC cells (data not shown).
No significant association was seen between pAKT473, p70S6K, expression and PFS or OS in univariate analysis (supplementary  Tables S2 and S5 , available at Annals of Oncology online).
associations between SNPs and PFS and OS
The primary tumour samples of RCC were available for 53 patients and, in all tissues, molecular analyses were carried out. Among the analysed genotypes, four genes were selected from the PI3K/AKT/mTOR pathway in these samples originating from RCC patients treated with everolimus; it was found that the SNP-PIK3CA:rs6443624 was associated with PFS. A calculation of the relative risk using a dominant model showed a twofold increase in the risk of disease progression in patients with genotype AC or AA compared with those with the variant CC (respectively HR: CC versus AA = 2.08, 95% CI 1.11-3.89, P = 0.0215 and HR: CC versus AC + AA = 1.87, 95% CI 1.02-3.44, P = 0.0452) (supplementary Table S3 , available at Annals of Oncology online).
Of the 13 SNPs assayed, only one, PI3KCA:rs6443624, was found to be significantly associated with survival in RCC patients treated with everolimus ( Figure 1) . A calculation of the relative risk using a dominant model showed a twofold increase in the risk of death in people with genotype AC or AA compared Table S4 , available at Annals of Oncology online).
univariate and multivariate analysis for PFS
There was no predictive significance of analysed genotype variables for PFS in patients treated with everolimus. In the analysed group of potential predictors of patho-clinical behaviour, a positive trend was observed for elevated LDH level, histological grade G3-4, baseline HGB in the normal range, with a corrected calcium level below 10 mg/dl. It has been found that the adverse independent predictors for everolimus therapy were histologic grade G1/2 [HR: 2.68 (95% CI 1.29-5.58, P = 0.0082)], increased LDH level before treatment [HR: 2.55 (95% CI 1.30-4.99, P = 0.0064)] and the PIK3CA gene variant rs6443624 [HR: AC + AA versus CC = 2.08 (95% CI 1.11-3.89, P = 0.0254)] (Table 3 and supplementary  Table S4 , available at Annals of Oncology online).
univariate and multivariate analysis for OS It was found that the prognostic factors for OS were baseline LDH level, corrected calcium level, the prognosis by MSKCC scale and prior treatment with sunitinib, sorafenib, or IFN-α.
In multivariate analysis, it was observed that the adverse independent prognostic factors were: elevated corrected calcium level (Table 3 and supplementary Table S5 , available at Annals of Oncology online).
discussion
The PI3K/AKT/mTOR pathway plays important roles in regulating cell growth, proliferation and cell death, and in a cancer cell this pathway is dysregulated. In our study, we decided to assess the role of the predictive and/or prognostic factors chosen from a set of clinical and pathological variables, but focusing on components of the PI3K/AKT/mTOR pathway. pAKT473 nuclear expression was found in 94.3% of patients, but we did not observe any association between the expression of pAKT473 and PFS or OS.
Schultz et al. [8] studied the role of proteins involved in the PI3K/AKT/mTOR pathway (including AKT) in patients with RCC. They compared the expression of selected proteins either in the primary tumours or in metastases originating from 176 patients who underwent nephrectomy due to benign lesions or RCC limited only to the kidney or metastatic disease. They observed that the expression of pAKT correlated with OS but not with disease-specific survival. In the multivariate analysis, they found that expression of this protein was not an independent prognostic factor. We confirm the results of Schultz et al. that pAKT473 has no clinical relevant both in PFS or OS.
Currently available data report for predictive significance of proteins PI3K/AKT/mTOR pathway in patients with mRCC treated with everolimus from one phase Ib study. Primary tumour tissue specimens derived from 18 mRCC patients before everolimus treatment were examined for the expression levels of proteins PI3K/AKT/mTOR pathway. Expression levels of phospho-AKT were not associated with efficacy of everolimus treatment with respect to CBR and PFS [9] . Soria et al. [10] sought novel biomarkers associated with the mTOR pathway in patients with smallcell lung cancer SCLC. In multivariate analysis, it they found that among the analysed biomarkers, pAKT473 and pAKT308 proved to be significant predictors for PFS. Additionally, the authors observed that high expression of both proteins had been an adverse predictor for response to everolimus. Contrary to these results, we did not find a predictive or prognostic role of the expression of pAKT and p70S6K proteins in patients with RCC treated with everolimus.
AKT protein plays a central role in the activation of mTOR and therefore is expected to behave synchronously with mTOR. However, we did not find a predictive role of the expression of pAKT in patients with mRCC treated with everolimus. The possible explanation for this fact comes from that AKT may not be the only pathway that activates mTOR. Recently, in the experimental study, Nawroth et al. [11] provided evidence for an alternative mTOR-independent but PI3K-dependent regulation of 4E-BP1. Crosstalk between PI3K and the MAPK signalling pathway is mediated via PI3K and indirect by S6K1 activity. Inhibition of MEK1/2 results in activation of AKT but not mTOR/S6K1 or 4E-BP1.
Genetic variation in the genes encoding the PI3K/AKT/ mTOR pathway may be responsible for the occurrence of resistance to various cytotoxic drugs used in cancer treatment. There are no published studies on the direct effect of genetic variation in the genes of this pathway on the clinical course of RCC. In our study, we evaluated 13 SNPs in four genes encoding the PI3K/AKT/mTOR pathway. Multivariate analysis revealed that the rs6443624 variant of the PIK3CA gene was the adverse independent prognostic and predictor factor in patients with RCC treated with everolimus in second and subsequent lines. Among the studies devoted to polymorphisms in genes involved in the PI3K/AKT/mTOR pathway in one authored by Hildebrandt et al. [12] showed the clinical significance of variation in the PI3K, PTEN, AKT1, AKT2 and FRAP1 genes in patients with oesophageal cancer who underwent surgery and subsequent chemoradiation. The authors found that genetic variation in AKT1, AKT2, and FRAP1 was significantly associated with survival. These results indicate that genetic variation may significantly influence the effect of therapy in patients with oesophageal cancer which can be used when choosing the right strategy treatment of this tumour.
An intra-tumoral heterogeneity appears to have a clinical role in the way how to build a personalised medicine strategy based on the development of new biomarkers. Gerlinger et al. [13] analysed intra-tumour heterogeneity based on exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple spatially separated samples obtained from primary RCC and associated metastatic sites in RCC patients treated with everolimus. Phylogenetic reconstruction showed branched evolutionary tumour growth, with an increase in the proportion of total somatic mutations from 63% to 69%, which was not detectable in every tumour region identified across multiple biopsies of two primary tumours and their associated metastatic sites. Intra-tumour heterogeneity mutations were observed for an auto-inhibitory domain of mTOR kinase, which correlated with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro. It was observed within different regions of the same tumour with good and unfavourable gene-expression signatures. The results of this work might be a serious challenge for personalised medicine and particularly for studies such as those which seek biomarkers of tumour response to specific therapies based on the analysis of single samples of the primary tumour.
Some latest evidence suggests that branched evolutionary tumour growth may contribute to intra-tumour phenotypic heterogeneicity both within a primary tumour and between primary and metastatic tumour sites [14] . It is generally considered to be highly possible that several areas of a primary tumour independently give rise to metastatic propensity and clonal diversity across different metastatic sites. Therefore, varying responses are observed across different metastatic sites in the same patient, so-called mixed response [15] .
In conclusion, this prospective phase II study showed no predictive or prognostic significance of investigated proteins from the PI3K/AKT/mTOR pathway assessed by IHC in primary tumour cells of RCC. The PIK3CA gene variant rs6443624 might be an independent predictor and prognostic factor. Serum levels of LDH and histologic grade may be new simple tests which, together with SNPs of the PI3KCA gene, can predict improved outcomes with everolimus therapy. Corrected calcium level and the PI3KCA polymorphism can predict the prognosis of patients with RCC. Further investigation is needed to confirm and validate these findings prospectively in other RCC trials.
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